Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$133.85

 2.43 (1.85%)

12/14/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress - December 10, 2018
CAMBRIDGE, Mass., and BEIJING, China, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 5, 2018
CAMBRIDGE, Mass. and BEIJING, China, Dec. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a co... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts